HC Wainwright Forecasts Septerna’s Q4 Earnings (NASDAQ:SEPN)

Septerna, Inc. (NASDAQ:SEPN) – Investment analysts at HC Wainwright decreased their Q4 2025 earnings estimates for Septerna in a report issued on Tuesday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.05) per share for the quarter, down from their previous estimate of $0.87. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna’s Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.25 EPS.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.28). The company had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%.

SEPN has been the subject of several other reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of Septerna in a research report on Friday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Septerna from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.75.

Septerna Price Performance

Shares of NASDAQ:SEPN traded down $0.65 during trading hours on Thursday, hitting $18.58. 19,405 shares of the company’s stock traded hands, compared to its average volume of 572,020. Septerna has a 1 year low of $4.17 and a 1 year high of $28.99. The firm has a market capitalization of $828.21 million and a P/E ratio of -12.38. The business has a fifty day moving average price of $19.07 and a 200-day moving average price of $13.61.

Hedge Funds Weigh In On Septerna

Institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in shares of Septerna during the third quarter worth about $36,000. Vanguard Group Inc. raised its position in shares of Septerna by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after purchasing an additional 104,394 shares during the last quarter. Covestor Ltd boosted its stake in Septerna by 55.8% in the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after purchasing an additional 1,296 shares in the last quarter. Rangeley Capital LLC grew its position in Septerna by 10.7% during the 2nd quarter. Rangeley Capital LLC now owns 58,605 shares of the company’s stock worth $619,000 after purchasing an additional 5,655 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new position in Septerna during the 2nd quarter valued at approximately $5,723,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.